Merck Board Appoints Panel for Vioxx Case
From Bloomberg News
Merck & Co.’s board appointed a committee of its members to review the company’s actions before the world’s biggest withdrawal of a prescription medicine, its Vioxx painkiller.
Merck faces more than 300 Vioxx lawsuits, the company said last month in a filing with the Securities and Exchange Commission.
The announcement was made after U.S. markets closed. Merck shares fell 23 cents to $27.89 on the New York Stock Exchange.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.